Last reviewed · How we verify
FerroGrad by Abbott
FerroGrad delivers iron in a sustained-release formulation to treat iron deficiency anemia by replenishing iron stores.
FerroGrad delivers iron in a sustained-release formulation to treat iron deficiency anemia by replenishing iron stores. Used for Iron deficiency anemia.
At a glance
| Generic name | FerroGrad by Abbott |
|---|---|
| Also known as | FerroGrad, Abbott |
| Sponsor | Clinica Fabia Mater |
| Drug class | Iron supplement |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
FerroGrad is an extended-release iron supplement that provides ferrous sulfate in a controlled manner to minimize gastrointestinal irritation while maintaining therapeutic iron levels. The sustained-release mechanism allows for better absorption and tolerability compared to immediate-release iron formulations, reducing the frequency of dosing required for iron replacement therapy.
Approved indications
- Iron deficiency anemia
Common side effects
- Constipation
- Nausea
- Abdominal discomfort
- Dark stools
Key clinical trials
- Bovine Lactoferrin Versus Ferrous Sulphate In The Treatment Of Iron Deficiency Anemia During Pregnancy (PHASE4)
- Bovine Lactoferrin to Prevent and Cure Iron Deficiency and Iron Deficiency Anemia in Complicated Pregnancies (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FerroGrad by Abbott CI brief — competitive landscape report
- FerroGrad by Abbott updates RSS · CI watch RSS
- Clinica Fabia Mater portfolio CI